Sequential combination therapy for newly diagnosed ITP in adults
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests a combination of multiple drugs given in sequence to adults with newly diagnosed immune thrombocytopenia (ITP), a condition of low platelets. The goal is to see if this approach improves platelet counts and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of primary ITP with a platelet count below 30,000 per microliter.
- You must not have had any prior ITP treatment except for short-term corticosteroids or IVIG (5 days or less).
- You must not have had a blood clot in an artery or vein within the past 3 months.
- You must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—avatrombopag and all-trans retinoic acid—in adults with persistent or chronic immune thrombocytopenia (ITP) whose platelet levels stay low despite prior treatments. The goal is to see if this combination can safely raise platelet counts and reduce bleeding risk.
This trial tests adding a new drug (ripertamab) to a standard ITP treatment (eltrombopag) for patients whose platelet count hasn't improved with steroids. The goal is to see if the combination works better at raising platelet counts and lowering bleeding risk.
This trial tests a combination of romiplostim (a platelet-boosting drug) and steroids as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this approach can safely and effectively raise platelet counts.
This trial tests combining two antibodies (anti-CD38 and rituximab) for adults with chronic ITP who haven't been helped by steroids or other standard treatments. The goal is to see if this drug pair can raise platelet counts and reduce bleeding risk.
This trial tests whether adding a new drug (telitacicept) to a standard platelet booster (eltrombopag) works better than eltrombopag alone for adults whose ITP has not responded to steroids.
This trial tests a medicine called romiplostim (Nplate) as a first treatment for adults newly diagnosed with ITP. It aims to see if it can safely raise platelet counts and reduce bleeding risk.
Hear when a new ITP - Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.